Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

Coronavirus Disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a crude case fatality rate of about 0.5–10 % depending on locality. A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamos...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Shuofeng, Chan, Jasper F.W., Chik, Kenn K.H., Chan, Chris C.Y., Tsang, Jessica O.L., Liang, Ronghui, Cao, Jianli, Tang, Kaiming, Chen, Lin-Lei, Wen, Kun, Cai, Jian-Piao, Ye, Zi-Wei, Lu, Gang, Chu, Hin, Jin, Dong-Yan, Yuen, Kwok-Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254006/
https://www.ncbi.nlm.nih.gov/pubmed/32473310
http://dx.doi.org/10.1016/j.phrs.2020.104960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254006/
https://www.ncbi.nlm.nih.gov/pubmed/32473310
http://dx.doi.org/10.1016/j.phrs.2020.104960

Ejemplares similares